[Treatment of gastric acid hypersecretion in the Zollinger-Ellison syndrome with a thioamide derivative (40749 RP). Comparison with ranitidine].
The efficacy of a new gastric antisecretory drug, 40749 RP, was studied in five cases of Zollinger-Ellison syndrome. Daily oral dosage was 2 mg/kg bw b.d. Clinical results and tolerance were excellent in all five cases (follow-up 1 to 16 months). In two cases, chronic duodenitis disappeared with 40749 RP only. Antisecretory activity was evaluated on basal acid output and 24 h pH profile. During 24 h period, the mean number of hours at or below pH 1.5, 2 and 3 obtained with 40749 RP in the five cases was 5, 9 and 12 h versus 13, 14 and 19 h with ranitidine. In all cases, basal acid output measured during one hour before fractional intake of 40749 RP was below 7 mmol/h during the first month of treatment. Clinical and biological results obtained with 40749 RP are similar to those obtained with omeprazole.
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000097:blood; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D011899:Ranitidine / Q000627:therapeutic use*; D013876:Thiophenes / Q000378:metabolism / Q000627:therapeutic use*; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D005755:Gastrins; D013876:Thiophenes; C034498:RP 40749; D011899:Ranitidine
Traitement de l'hypersécrétion gastrique acide du syndrome de Zollinger-Ellison par un dérivé des thioamides (40749 RP). Comparaison avec la ranitidine.